Elanco's third quarter performance was marked by strong revenue growth across both pet and farm animal segments, with management highlighting U.S. Farm Animal up 20% and solid momentum in U.S. pet health. CEO Jeffrey Simmons attributed the results to the company’s expanding innovation portfolio, particularly new products like Credelio Quattro and Zenrelia. Despite these achievements and operational improvements, the market responded negatively, reflecting ongoing concerns about margin sustainability and competitive pressures. CFO Bob VanHimbergen noted that increased investments in global pet health launches contributed to operating expense growth, though these were partially offset by productivity gains and deleveraging efforts.
Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).
Elanco (ELAN) Q3 CY2025 Highlights:
- Revenue: $1.14 billion vs analyst estimates of $1.09 billion (10.4% year-on-year growth, 4.1% beat)
- Adjusted EPS: $0.19 vs analyst estimates of $0.13 (43.9% beat)
- Adjusted EBITDA: $198 million vs analyst estimates of $173.3 million (17.4% margin, 14.3% beat)
- Revenue Guidance for Q4 CY2025 is $1.10 billion at the midpoint, above analyst estimates of $1.08 billion
- Management raised its full-year Adjusted EPS guidance to $0.93 at the midpoint, a 5.1% increase
- EBITDA guidance for the full year is $890 million at the midpoint, above analyst estimates of $874.1 million
- Operating Margin: 0.2%, up from -2.1% in the same quarter last year
- Constant Currency Revenue rose 9% year on year (1% in the same quarter last year)
- Market Capitalization: $11.36 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Elanco’s Q3 Earnings Call
- Umer Raffat (Evercore): Asked about the sales trajectory and peak potential of Credelio Quattro. CEO Jeffrey Simmons clarified $100 million in sales was cumulative year-to-date, not just Q3, and suggested significant global runway remains as the product is only in one market so far.
- Jonathan Block (Stifel): Sought details on Zenrelia’s U.S. label updates and international share gains. Simmons explained that recent U.S. label changes improved market acceptance, and further regulatory submissions aim to align the label with international standards, supporting additional growth.
- Michael Ryskin (Bank of America): Probed the sustainability of margin gains amid ongoing investment in innovation and mounting competition. CFO Bob VanHimbergen noted that innovation products already have higher margins, and the Elanco Ascend program will drive further efficiencies even as competitive pressures increase.
- Andrea Alfonso (UBS): Questioned whether macro headwinds and declines in U.S. vet visits were impacting results. Simmons responded that Elanco’s strategy and portfolio diversity insulate it from these trends, citing strong market growth in endecto and dermatology categories.
- Daniel Clark (Leerink Partners): Asked about the drivers behind the increased innovation revenue guidance and future growth expectations for the innovation basket. VanHimbergen pointed to strength from products like Experior, AdTab, Credelio, and Zenrelia, with seasonality and market momentum supporting ongoing gains.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will focus on (1) the global rollout and adoption rates of Credelio Quattro and Zenrelia, (2) the effectiveness and financial impact of the Elanco Ascend margin improvement program, and (3) signs that Elanco can maintain or expand market share despite competitive launches in parasiticides and dermatology. Progress in deleveraging and execution of the company’s innovation pipeline will also be closely watched.
Elanco currently trades at $22.86, up from $22.50 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free for active Edge members).
Our Favorite Stocks Right Now
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
